单株抗体市场规模、份额、成长分析，按来源类型、按生产类型、按应用、按最终用途、按地区 - 行业预测，2024-2031 年

2022年全球单株抗体市场规模估值为2,110亿美元，预测期间（2024-2031年）复合年增长率为11.5%，从2023年的2,352.7亿美元增至2031年的5,620.3亿美元，预估也会增长。

单株抗体 (mAb) 是透过克隆特定白血球从单一细胞株产生的抗体。由于其高特异性和功效，这些抗体被用于药物开发和作为各种疾病的治疗剂。全球慢性病盛行率的上升预计将在未来几年推动单株抗体市场的显着成长。此外，随着医学研发的大量投资以及生物技术的进步，对这些抗体的需求预计将进一步增加。分子生物学的进步预计也将为单株抗体市场做出积极贡献，促进其销售和应用。随着单株抗体在医疗保健、製药和生物技术领域的应用不断扩大，该领域的供应商和开发商正在出现新的机会。然而，该市场面临开发成本高、上市时间长和安全问题等挑战，可能会阻碍成长。随着市场的发展，这些因素将继续成为重要的考虑因素。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 市场生态系统
• 供应链分析
• 案例研究分析
• PESTEL分析
• 监管分析
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

单株抗体市场：依来源类型

• 市场概况
• 鼠
• 嵌合体
• 人性化
• 人类

单株抗体市场：依生产类型

• 市场概况
• In vivo
• In vitro

单株抗体市场：依应用分类

• 市场概况
• 肿瘤学
• 自体免疫疾病
• 感染疾病
• 神经系统疾病
• 其他的

单株抗体市场：依最终用途分类

• 市场概况
• 医院
• 专业中心
• 其他的

单株抗体市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• GlaxoSmithKline plc（UK）
• Amgen Inc.（US）
• Merck & Co., Inc.（US）
• Daiichi Sankyo Company, Limited（Japan）
• Abbott Laboratories（US）
• AstraZeneca plc（UK）
• Eli Lilly and Company（US）
• Johnson & Johnson Services, Inc.（US）
• Bayer AG（Germany）
• Bristol Myers Squibb（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Viatris Inc.（US）
• Biogen Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• Novo Nordisk A/S（Denmark）
• Sanofi SA（France）
• Merck KGaA（Germany）
• Genmab A/S（Denmark）
• Regeneron Pharmaceuticals, Inc.（US）
• Incyte Corporation（US）

Global Monoclonal Antibodies Market size was valued at USD 211 billion in 2022 and is poised to grow from USD 235.27 billion in 2023 to USD 562.03 billion by 2031, growing at a CAGR of 11.5% during the forecast period (2024-2031).

Monoclonal antibodies (mAbs) are antibodies generated from a single cell lineage by cloning a specific white blood cell. These antibodies are utilized in drug development and as treatments for a variety of diseases due to their high specificity and effectiveness. The increasing prevalence of chronic diseases globally is expected to drive significant growth in the monoclonal antibody market in the coming years. Additionally, substantial investments in medical research and development, along with advancements in biotechnology, are anticipated to further enhance the demand for these antibodies. The progress in molecular biology is also expected to contribute positively to the monoclonal antibody market, boosting their sales and application. As monoclonal antibodies find expanding uses across healthcare, pharmaceuticals, and biotechnology sectors, new opportunities are emerging for suppliers and developers in this field. However, the market faces challenges, including high development costs, extended time-to-market, and safety concerns, which may hinder its growth. These factors are likely to remain key considerations as the market evolves.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibodies Market Segmental Analysis

Global Monoclonal Antibodies Market is segmented by Source type, Production Type, Application, End-use, and region. Based on Source type, the market is segmented into Murine, Chimeric, Humanized, and Human. Based on Production Type, the market is segmented into In Vivo, and In Vitro. Based on Application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, and Others. Based on End-use, the market is segmented into Hospitals, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Monoclonal Antibodies Market

The increasing global prevalence of chronic diseases has heightened the need for innovative treatments and therapeutics, leading to greater investments in medical research and development. Monoclonal antibodies are central to this R&D, offering critical solutions for managing a variety of chronic conditions. As a result, the growing reliance on monoclonal antibodies in the development of new therapies is expected to drive further market expansion. This trend suggests that the market for monoclonal antibodies will continue to grow as research progresses and new applications are discovered.

Restraints in the Global Monoclonal Antibodies Market

The development of monoclonal antibodies involves intricate and time-consuming research techniques, contributing to high R&D costs. These substantial expenses are reflected in the final product prices, which can limit market growth. The elevated cost of developing monoclonal antibodies makes the end products expensive, posing a challenge to market expansion. Consequently, the high development costs are a significant factor impacting the overall growth of the monoclonal antibody market.

Market Trends of the Global Monoclonal Antibodies Market

The expiration of patents for monoclonal antibodies presents promising opportunities for the development of biosimilars and biobetters. Companies can focus their research and development efforts on creating biosimilars for well-established monoclonal antibodies whose patents are nearing expiration. By investing in the development of these biosimilars, companies have the potential to capitalize on the market for these products and achieve significant long-term profits. This strategic move can offer substantial financial benefits as the market for original monoclonal antibodies becomes more competitive.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Ecosystem of the Market
• Supply chain Analysis
• Case study Analysis
• PESTEL Analysis
• Regulatory Analysis
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Monoclonal Antibodies Market by Source type

• Market Overview
• Murine
• Chimeric
• Humanized
• Human

Monoclonal Antibodies Market by Production Type

• Market Overview
• In Vivo
• In Vitro

Monoclonal Antibodies Market by Application

• Market Overview
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

Monoclonal Antibodies Market by End-use

• Market Overview
• Hospitals
• Specialty Centers
• Others

Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments